AR and prostate carcinoma: Therefore, clinical therapies use anti-androgens (Flutamide, Bicalutamide, Enzalutamide, Apalutamide, and Darolutamide) to competitively suppress androgen-induced AR activation or CYP17A1 inhibitor (Abiraterone) to reduce androgen production in prostate cancer tissues (5).